1. Home
  2. LAC vs APMD Comparison

LAC vs APMD Comparison

Compare LAC & APMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lithium Americas Corp.

LAC

Lithium Americas Corp.

HOLD

Current Price

$3.01

Market Cap

1.0B

ML Signal

HOLD

APMD

Apnimed Inc. Common Stock

N/A

Current Price

$26.71

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LAC
APMD
Founded
2023
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2023
2026

Fundamental Metrics

Financial Performance
Metric
LAC
APMD
Price
$3.01
$26.71
Analyst Decision
Hold
Analyst Count
7
0
Target Price
$6.14
N/A
AVG Volume (30 Days)
9.4M
380.2K
Earning Date
05-14-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.67
$20.02
52 Week High
$10.52
$35.29

Technical Indicators

Market Signals
Indicator
LAC
APMD
Relative Strength Index (RSI) 40.15 48.62
Support Level $2.90 $23.98
Resistance Level $3.58 $30.34
Average True Range (ATR) 0.15 3.25
MACD 0.00 -0.41
Stochastic Oscillator 5.15 9.43

Price Performance

Historical Comparison
LAC
APMD

About LAC Lithium Americas Corp.

Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.

About APMD Apnimed Inc. Common Stock

Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).

Share on Social Networks: